Responses

Download PDFPDF

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Decline in genital warts in Melbourne: How much is really due to the implementation of the Australian national quadrivalent human papillomavirus vaccination programme?

    We read the article by Fairley et al(1) with great interest. The authors concluded that the decline in genital warts among women in the age groups (<28 years) targeted for vaccination provides strong evidence for the population-level effectiveness of the vaccine. They also report that this conclusion was strengthened by the fact that no significant decline in genital warts post vaccination has been noted among other ri...

    Show More
    Conflict of Interest:
    None declared.